Evotec SE — M&A Activity 2013

Jan 2, 2013

News Details

Corporate | 2 January 2013 07:29

Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy

Evotec AG / Key word(s): Alliance

02.01.2013 / 07:29

---

Hamburg, Germany - 02 January 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that Evotec and Apeiron Biologics have entered
into a research collaboration with the objective of developing
immunomodulatory lead compounds for the treatment of cancer. Apeiron
Biologics will contribute in vitro and in vivo pharmacology expertise to
this collaboration while Evotec will be responsible for medicinal chemistry
as well as chemical proteomics. The collaboration is based on the
successful outcome of a phenotypic high throughput screen previously
commissioned by Apeiron Biologics to Evotec.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We look
forward to continue working with Apeiron on this important project. The
collaboration highlights the strength of Evotec's phenotypic screening
capabilities to identify novel mechanisms and hits in important therapeutic
areas.'

Dr Hans Loibner, Chief Executive Officer of Apeiron Biologics, added: 'We
were excited about the outcome of the primary screen and look forward to
refining the hit compounds in this collaboration applying our immunological
know-how. There is no doubt that immunomodulatory compounds like these
carry huge therapeutic and commercial potential.'

No financial details are disclosed.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen MedImmune/AstraZeneca, and Ono
Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in
the field of Alzheimer's disease. For additional information please go to
www.evotec.com.

ABOUT APEIRON Biologics AG
Apeiron is a mostly privately financed biotech company in Vienna that
develops immunological/biological therapies against cancer. Its portfolio
consists of five clinical projects (lead in phase III) as well as some
preclinical approaches. The most advanced project APN311 is an antibody to
treat the pediatric cancer neuroblastoma. The immunocytokine hu14.18-IL2
(APN301) is being developed clinically in neuroblastoma as well as in
melanoma. Moreover, recombinant human superoxide dismutase is in clinical
development, notably in a topical liposomal formulation (APN201) as a
potent anti-inflammatory tissue-protective biologic. Two complementary
approaches are pursued (APN401, APN411) that stimulate immune cells in a
novel way to treat cancer more effectively. The recombinant human
Angiotensin Converting Enzyme 2 (GSK2586881, previously APN01) was licensed
out to GlaxoSmithKline in early 2010 and is currently investigated in a
phase II trial in patients suffering from acute lung injury. Apeiron
started operations in 2006 and has 23 employees as of today.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: +44.(0)1235.441676,
mario.polywka@evotec.com

End of Corporate News

---

02.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

197962 02.01.2013